Chugai strikes European deal for Helsinn's anamorelin

Chugai's UK-based European marketing subsidiary has acquired rights in selected major European markets to Helsinn's ghrelin receptor agonist anamorelin, which it will commercialize for anorexia-cachexia syndrome related to advanced non-small lung cancer.